ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,346.99
      -0.11%
      US Tech 100
      18,488.00
      -0.25%
      Dow Jones
      38,798.99
      -0.22%
      Brent Oil
      79.395
      0.00%
      Bitcoin
      69,489.83
      0.23%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Pozen, Inc. (MM) (POZN)

      7. Pozen, Inc. (MM) (POZN) News

      POZN

      Pozen, Inc. (MM) (POZN)

      Pozen, Inc. (MM)
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:POZN
      DateTimeSourceHeadlineSymbolCompany
      2:15PMiHub NewswireFeaturedDaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio
      03/14/20163:08PMEdgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:POZNPozen, Inc. (MM)
      03/14/20161:23PMEdgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:POZNPozen, Inc. (MM)
      03/14/20161:21PMEdgar (US Regulatory)Withdrawal of Registration Statement (rw)NASDAQ:POZNPozen, Inc. (MM)
      10/19/20099:01AMPR Newswire (US)Patients Taking VIMOVO(TM) Showed a Decrease in Incidence of NSAID-Associated UlcersNASDAQ:POZN
      10/16/20098:45AMDow Jones NewsAstraZeneca Submits EU Marketing Application For VimovoNASDAQ:POZNPozen Inc.
      08/31/20098:39AMDow Jones NewsPozen Earns $10 Million From AstraZeneca As FDA Accepts Drug ApplicationNASDAQ:POZNPozen Inc.
      06/30/20098:57AMDow Jones NewsAstraZeneca Partner Pozen Submits PN400 New Drug ApplicationNASDAQ:POZNPozen Inc.
      06/30/20098:57AMDow Jones NewsAstraZeneca Partner Pozen Submits PN400 New Drug ApplicationNASDAQ:POZNPozen Inc.
      06/08/20071:00PMPR Newswire (US)Trexima(TM) (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple AttacksNASDAQ:POZN
      05/02/20073:12PMPR Newswire (US)Trexima(TM) (Sumatriptan/Naproxen Sodium) Demonstrated Efficacy Across Multiple Migraine AttacksNASDAQ:POZN
      05/02/20073:09PMPR Newswire (US)Trexima(TM) (Sumatriptan/Naproxen Sodium) Provided Relief of Both Traditional and Non-traditional Migraine SymptomsNASDAQ:POZN
       Showing the most relevant articles for your search:NASDAQ:POZN